Southern Research

Last updated

Southern Research is a not-for-profit US 501(c)(3) research organization that conducts basic and applied research for commercial and non-commercial organizations across four divisions: Drug Development, Drug Discovery, Energy & Environment, and Engineering. [1]

Contents

History

Southern Research was founded in Birmingham, Alabama, on October 11, 1941 by Thomas Martin as the Alabama Research Institute. [2]

Although Martin was named chairman of the newly chartered organization in December, 1941, activities were put on hold in the aftermath of the attack on Pearl Harbor and the beginning of US involvement in World War II. Two years later, in December 1943, with a promise of support from the Alabama Power Company, Martin reengaged the Alabama's industrial leaders and received over $100,000 in philanthropic donations. [3]

Alabama Power Company pledged an additional US$15,000 per year for five years, $75,000 total, and this was enough for the organization to finance laboratory space and hire researchers and staff. The following year, 1944, the decision was made to change the institute's name from Alabama Research Institute, to Southern Research Institute. [3]

Around this same time, Southern Research Institute hired its first director, Wilbur Lazier. Though he only stayed in this role for four years, Lazier is credited with recruiting many figures that shaped the history of the organization, including Howard E. Skipper. [4]

Southern Research celebrated its 75th Anniversary in October, 2016. [5] In celebration of this milestone the director of National Institutes of Health (NIH), Francis Collins, produced a video congratulating the organization on its anniversary. [6]

Leadership

In June 2021, Josh Carpenter was named president and CEO of Southern Research. Before joining Southern Research, Carpenter served as director of the Innovation and Economic Opportunity Department for the City of Birmingham, where he led the city’s efforts in workforce development, COVID recovery and business expansion. Previously, he worked as the director of External Affairs at the University of Alabama at Birmingham, as an assistant professor of economics at UAB and as a non-resident senior fellow at The Brookings Institution.

Southern Research Past Presidents
YearName
2013 – 2019Arthur J. Tipton, PhD
2006 - 2013John A. Secrist III, PhD
2001 - 2006Robert C. Lonergan
1999 - 2000J. David Prejean, PhD
1997 - 1999Gilbert E. Dwyer
1987 - 1997John W. Rouse Jr., PhD
1981 - 1987Sabert Oglesby Jr.
1974 - 1980Howard E. Skipper, PhD
1948 - 1974William M. Murray Jr., PhD
1944 - 1948Wilbur A. Lazier, PhD

Drug development

Southern Research's Drug Development division is the largest of the organization's four divisions. Set up like a contract research organization (CRO), Southern Research provides commercial and government clients with nonclinical and clinical trial support services. [7] They offer studies including both in vitro and in vivo testing of small molecule compounds, vaccines, biologics, and other test articles in therapeutic areas including infectious disease, CNS and cancer. Current service areas include: Bioanalytical Analysis; Anticancer Efficacy Services; Immunology; Infectious Disease; Pathology; and Consulting.

Drug discovery

Southern Research's Drug Discovery division conducts research focused on oncology, infectious disease, and neuroscience. Their current service areas include: High Throughput Screening (THS), [8] Chemistry, Oncology, Infectious Disease, Neuroscience, and the Center for Neuromolecular Research.

Southern Research is a founding member of the Alabama Drug Discovery Alliance (ADDA) along with the University of Alabama at Birmingham School of Medicine (SOM). The UAB Center for Clinical and Translational Science (CCTS), and the UAB Comprehensive Cancer Center (CCC) are also crucial contributors to the ADDA. [9]

Mark J. Suto is vice president of Drug Discovery at Southern Research. [10] [11] He has been named a Fellow of the National Academy of Inventors (NAI) in recognition of his wide-ranging contributions to pharmaceutical research and drug discovery efforts. [12]

Cancer research

Southern Research cancer research program was started in 1946 with a $25,000 philanthropic donation from Mobile, AL businessman, Ben E. May. [13]

The organization's scientists are credited with the discovery of seven Food and Drug Administration (FDA) approved anti-cancer drugs, including carmustine, lomustine, dacarbazine developed by Y Fulmer Shealy, fludarabine, amifostine, clofarabine and the latest pralatrexate (approved in 2009). Notable cancer researchers who worked at the institute include Y Fulmer Shealy Howard E. Skipper, John Montgomery, Frank Schabel and Lee Bennett Jr.

Clofarabine [14] is a nucleoside discovered at Southern Research that eventually received FDA approval. Clofarabine, a second-generation nucleoside analogue received accelerated approval from the US FDA at the end of 2004 for the treatment of paediatric patients 1–21 years old with relapsed or refractory acute lymphoblastic leukaemia after at least two prior regimens. It is the first such drug to be approved for paediatric leukaemia in more than a decade, and the first to receive approval for paediatric use before adult use. [14]

Pralatrexate is another anticancer drug whose discovery was a result of contributions from medicinal chemists at Southern Research along with chemists from SRI International and Memorial Sloan-Kettering Cancer Center. The US FDA announced the approval of pralatrexate in 2009 for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). [15] Research on drugs of this class began at SRI International in the 1950s. Pralatrexate was first prepared there by Dr. Joseph DeGraw and Dr. William Colwell. Dr. Robert Piper at Southern Research synthesized the key starting material (a bromomethyl compound) which was used to prepare the intermediates needed to make multigram quantities of high purity final compound. Multiple issued patents on this compound are jointly owned by Southern Research, SRI International and Memorial Sloan Kettering and licensed to Allos Therapeutics.

Molecular libraries program

[16] MLP was founded by the NIH to fund research aimed at identifying new chemical probes against biological targets that might be amenable for drug therapy. Southern Research was one of eight extramural institutes selected for this initiative along with the Broad Institute, Sanford-Burnham Medical Research Institute, Johns Hopkins University, Scripps Research Institute, Vanderbilt University, University of New Mexico and the University of Kansas. [17] In addition the MLP initiative also included an NIH intramural site: the National Center for Chemical Genomics (NCGC).

Energy and environment

Southern Research's Energy & Environment division focuses on technology for clean energy, clean air, and clean water. Southern Research develops and tests air and water emissions control technologies for leading utilities, industrial manufacturers, municipal water utilities, and related trade organizations. The division has also historically partnered with private sector firms and government agencies to develop new technologies that transform energy generation, chemical synthesis, and air and water purification. [18]

Engineering

Southern Research engineers have worked with the National Aeronautics and Space Administration (NASA), the U.S. Military and other organizations. [19]

Current areas include: Non destructive evaluation of materials; Chemistry and Physics of Materials; Electrical, EO/IR, and Mechanical Systems; Hypersonic Structures; Space Structures Characterization; Mechanical Testing of Materials Structures and Components; and Thermal Testing of Materials.

Michael D. Johns is the vice president of Engineering at Southern Research. [20] He also serves on NASA Space Technology Mission Directorate’s Technology, Innovation and Engineering Committee. [21]

AIMTech

In 2014, Southern Research and the University of Alabama at Birmingham formed the Alliance for Innovative Medical Technology (AIMTech) to develop new medical devices to improve healthcare. [22]

The creation of medical devices are across all five specializations: Cardiology, Orthopedics, Ophthalmology, Rehabilitation and Trauma. The goal is for the first group of AIMTech-created medical devices to hit the market by 2020. By comparison, it can take 10 years to create an FDA approved drug. [23]

In 2016, AIMTech was awarded a $500,000 U.S. Department of Commerce grant to expand medical device innovation and commercialization. [24] [25]

Patents

Related Research Articles

<span class="mw-page-title-main">Food and Drug Administration</span> United States federal agency

The United States Food and Drug Administration is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, caffeine products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics, animal foods & feed and veterinary products.

<span class="mw-page-title-main">National Institutes of Health</span> US government medical research agency

The National Institutes of Health, commonly referred to as NIH, is the primary agency of the United States government responsible for biomedical and public health research. It was founded in the late 1880s and is now part of the United States Department of Health and Human Services. Many NIH facilities are located in Bethesda, Maryland, and other nearby suburbs of the Washington metropolitan area, with other primary facilities in the Research Triangle Park in North Carolina and smaller satellite facilities located around the United States. The NIH conducts its own scientific research through the NIH Intramural Research Program (IRP) and provides major biomedical research funding to non-NIH research facilities through its Extramural Research Program.

The National Cancer Institute (NCI) coordinates the United States National Cancer Program and is part of the National Institutes of Health (NIH), which is one of eleven agencies that are part of the U.S. Department of Health and Human Services. The NCI conducts and supports research, training, health information dissemination, and other activities related to the causes, prevention, diagnosis, and treatment of cancer; the supportive care of cancer patients and their families; and cancer survivorship.

<span class="mw-page-title-main">Amgen</span> American multinational biopharmaceutical company

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980. Amgen's Thousand Oaks staff in 2017 numbered 5,125 and included hundreds of scientists, making Amgen the largest employer in Ventura County. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.

<span class="mw-page-title-main">Scripps Research</span> Nonprofit American medical research institute

Scripps Research, previously known as The Scripps Research Institute (TSRI), is a nonprofit American medical research facility that focuses on research and education in the biomedical sciences. Headquartered in San Diego, California, the institute has over 170 laboratories employing 2,100 scientists, technicians, graduate students, and administrative and other staff, making it the largest private, non-profit biomedical research organization in the United States and among the largest in the world.

<span class="mw-page-title-main">Pralatrexate</span>

Pralatrexate, sold under the brand name Folotyn, is a medication used for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).

<span class="mw-page-title-main">Memorial Sloan Kettering Cancer Center</span> Hospital in New York City, US

Memorial Sloan Kettering Cancer Center is a cancer treatment and research institution in the borough of Manhattan in New York City, founded in 1884 as the New York Cancer Hospital. MSKCC is one of 52 National Cancer Institute–designated Comprehensive Cancer Centers. Its main campus is located at 1275 York Avenue, between 67th and 68th streets, in Manhattan.

<span class="mw-page-title-main">Gemcitabine</span> Chemical compound

Gemcitabine, with brand names including Gemzar, is a chemotherapy medication. It treats cancers including testicular cancer, breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer. It is administered by intravenous infusion. It acts against neoplastic growth, and it inhibits the replication of Orthohepevirus A, the causative agent of Hepatitis E, through upregulation of interferon signaling.

<span class="mw-page-title-main">Medical research</span> Wide array of research

Medical research, also known as experimental medicine, encompasses a wide array of research, extending from "basic research", – involving fundamental scientific principles that may apply to a preclinical understanding – to clinical research, which involves studies of people who may be subjects in clinical trials. Within this spectrum is applied research, or translational research, conducted to expand knowledge in the field of medicine.

<span class="mw-page-title-main">H. Lee Moffitt Cancer Center & Research Institute</span> Hospital in Florida, United States

Houston Lee Moffitt Cancer Center & Research Institute is a nonprofit cancer treatment and research center located in Tampa, Florida. Established in 1981 by the Florida Legislature, the hospital opened in October 1986 on the University of South Florida's campus. Moffitt is one of two National Cancer Institute-designated Comprehensive Cancer Centers based in Florida. In 2021, U.S. News & World Report ranked Moffitt Cancer Center as a top 30 cancer hospital in the United States.

Clinical research is a branch of healthcare science that determines the safety and effectiveness (efficacy) of medications, devices, diagnostic products and treatment regimens intended for human use. These may be used for prevention, treatment, diagnosis or for relieving symptoms of a disease. Clinical research is different from clinical practice. In clinical practice established treatments are used, while in clinical research evidence is collected to establish a treatment.

In medicine, an indication is a valid reason to use a certain test, medication, procedure, or surgery. There can be multiple indications to use a procedure or medication. An indication can commonly be confused with the term diagnosis. A diagnosis is the assessment that a particular [medical] condition is present while an indication is a reason for use. The opposite of an indication is a contraindication, a reason to withhold a certain medical treatment because the risks of treatment clearly outweigh the benefits.

<span class="mw-page-title-main">Stephen Hahn</span> 24th Commissioner of Food and Drugs (US FDA)

Stephen Michael Hahn is an American physician who served as the Commissioner of Food and Drugs from 2019 to 2021. Before becoming Commissioner, he was an oncologist serving as Chief Medical Executive of the MD Anderson Cancer Center.

Clinical and Translational Science Award (CTSA) is a type of U.S. federal grant administered by the National Center for Advancing Translational Sciences, part of the National Institutes of Health. The CTSA program began in October 2006 under the auspices of the National Center for Research Resources with a consortium of 12 academic health centers. The program was fully implemented in 2012, comprising 60 grantee institutions and their partners.

Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Moxetumomab pasudotox is a CD22-directed cytotoxin and is the first of this type of treatment for adults with HCL. The drug consists of the binding fragment (Fv) of an anti-CD22 antibody fused to a toxin called PE38. This toxin is a 38 kDa fragment of Pseudomonas exotoxin A.

<span class="mw-page-title-main">NIH Intramural Research Program</span> Internal research program of the National Institutes of Health

The NIH Intramural Research Program (IRP) is the internal research program of the National Institutes of Health (NIH), known for its synergistic approach to biomedical science. With 1,200 Principal Investigators and over 4,000 Postdoctoral Fellows conducting basic, translational, and clinical research, the NIH Intramural Research Program is the largest biomedical research institution on earth. The unique funding environment of the IRP facilitates opportunities to conduct both long-term and high-impact science that would otherwise be difficult to undertake. With rigorous external reviews ensuring that only the most outstanding research secures funding, the IRP is responsible for many scientific accomplishments, including the discovery of fluoride to prevent tooth decay, the use of lithium to manage bipolar disorder, and the creation of vaccines against hepatitis, Hemophilus influenzae (Hib), and human papillomavirus (HPV). In addition, the IRP has also produced or trained 21 Nobel Prize-winning scientists.

<span class="mw-page-title-main">Foundation for the National Institutes of Health</span>

The Foundation for the National Institutes of Health (FNIH) is a not-for-profit, 501(c)(3) charitable organization established by the US Congress in 1990. Located in North Bethesda, MD, the FNIH raises private-sector funds, and creates and manages alliances with public and private institutions in support of the mission of the National Institutes of Health (NIH).

<span class="mw-page-title-main">21st Century Cures Act</span> Bill enacted by the 114th United States Congress

The 21st Century Cures Act is a United States law enacted by the 114th United States Congress in December 2016 and then signed into law on December 13, 2016. It authorized $6.3 billion in funding, mostly for the National Institutes of Health. The act was supported especially by large pharmaceutical manufacturers and was opposed especially by some consumer organizations.

<span class="mw-page-title-main">Blue Ridge Institute for Medical Research</span>

The Blue Ridge Institute for Medical Research (BRIMR) is an independent, non-profit, scientific research institute located in Horse Shoe, North Carolina. The Institute was founded by Robert Roskoski Jr., who serves as President and Scientific Director.

<span class="mw-page-title-main">Ofelia Olivero</span> Argentine-American biologist

Ofelia Ana Olivero is an Argentine-American biologist specialized in HIV/AIDS and biomedical research. She pioneered the discovery of nucleoside analogs induced centrosomal amplification and aneuploidy while working as a senior staff scientist at the National Cancer Institute (NCI). In 2016, she became chief of the NCI diversity intramural workforce branch.

References

  1. ↑ "About Southern Research". Southern Research. Archived from the original on 2016-10-13. Retrieved 2016-11-15.
  2. ↑ "Tom Martin, Alabama Power and the founding of Southern Research". Alabama News Center. 7 October 2016. Archived from the original on 2019-02-16. Retrieved 2020-03-04.
  3. 1 2 "Alabama Power and the founding of Southern Research". Alabama%20News%20Center. Alabama News Center. Archived from the original on 2019-02-16. Retrieved 2020-03-04.
  4. ↑ "Encyclopedia of Alabama". Archived from the original on 2019-05-22. Retrieved 2020-03-04.
  5. ↑ "Southern Research at 75: Discovering cancer drugs and extending lives". Southern Research. Archived from the original on 2017-06-09. Retrieved 2020-03-04.
  6. ↑ "NIH director thanks Southern Research for 'treatments, cures and real hope'". Southern Research.
  7. ↑ "Cyclenium Pharma and Southern Research Institute Announce Drug Discovery and Development Collaboration". US Newswire. Archived from the original on 2016-11-17. Retrieved 2020-03-04.
  8. ↑ "Southern Research contracted for Zika drug discovery". Birmingham Business Journal. Archived from the original on 2017-06-10. Retrieved 2020-03-04.
  9. ↑ "Southern Research: Making Strides in Life-Changing Science for 75 Years". Protective Newsroom. Archived from the original on 2017-02-01. Retrieved 2020-03-04.
  10. ↑ "Southern Research Institute names Dr. Mark Suto as VP of Drug Discovery Division". AL.com. AL.com. 12 August 2011. Archived from the original on 2018-09-08. Retrieved 2020-03-04.
  11. ↑ "Southern Research". Archived from the original on 2017-05-29. Retrieved 2020-03-04.
  12. ↑ "Drug discovery scientist Mark Suto named to National Academy of Inventors". Yahoo. Archived from the original on 2017-08-19. Retrieved 2020-03-04.
  13. ↑ "Ben May's Gift Launches Cancer Program". Alabama News Center. 3 October 2016. Archived from the original on 2019-02-20. Retrieved 2020-03-04.
  14. 1 2 Bonate, Peter L.; Arthaud, Larry; Cantrell, William R.; Stephenson, Katherine; Secrist, John A.; Weitman, Steve (2006). "Discovery and development of clofarabine: a nucleoside analogue for treating cancer". Nature Reviews Drug Discovery. 5 (10): 855–63. doi:10.1038/nrd2055. PMID   17016426. S2CID   21361350.
  15. ↑ "FDA Approval for Pralatrexate - National Cancer Institute". Archived from the original on 2010-12-21. Retrieved 2009-12-05.
  16. ↑ "Molecular Libraries Program » Pilot Program". Archived from the original on 2011-03-22. Retrieved 2011-03-06.
  17. ↑ "The NIH Molecular Libraries Program: Identifying Chemical Probes for New Medicines | BioScreening.net". Archived from the original on 2011-03-19. Retrieved 2011-03-06.
  18. ↑ Harney, Erin (23 September 2016). "Alabama News Center". Alabama News Center. Archived from the original on 2019-02-13. Retrieved 2020-03-04.
  19. ↑ Beyerle, Dana (11 August 2016). "Southern Research New NASA Contract of Nearly $10 million". Business Council of Alabama. Archived from the original on 2019-07-08. Retrieved 2020-03-04.
  20. ↑ "Michael D. Johns Named to Top Engineering Post". The Free Library. The Free Library. Archived from the original on 2016-12-20. Retrieved 2020-03-04.
  21. ↑ "How Southern Research helped the program log 542 million miles". Southern Research. Archived from the original on 2018-10-19. Retrieved 2020-03-04.
  22. ↑ "U.S. Economic Development Administration". U.S. Economic Development Administration. Archived from the original on 2018-09-07. Retrieved 2020-03-04.
  23. ↑ "EDA.gov". U.S. Economic Development Administration. Archived from the original on 2018-09-07. Retrieved 2020-03-04.
  24. ↑ "Southern Research awarded $500,000 U.S. Department of Commerce grant to expand medical device innovation and commercialization". Yahoo. Yahoo. Archived from the original on 2016-12-21. Retrieved 2020-03-04.
  25. ↑ "Southern Research awarded $500,000 U.S. Department of Commerce grant to expand medical device innovation and commercialization". Southern Research. Archived from the original on 2017-06-09. Retrieved 2020-03-04.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.